Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rivaroxaban for isolated distal deep vein thrombosis with elevated D-dimer (IDDVT-D)
ChiCTR2600126943Phase 4Not yet recruiting
- Sponsor
- Shanghai Ninth People's Hospital
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in deep vein thrombosis (DVT) comparing Anticoagulant Treatment Group (rivaroxaban) with Control Group (placebo) (2 arms). Primary endpoint: Incidence of thrombus progression at 12 weeks after medication. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
rivaroxaban
03
Conditions
deep vein thrombosis (DVT)
Beyond the preview
Go deeper on ChiCTR2600126943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126943.